Quan Vu - 180 Life COO Officer
| ATNF Stock | USD 1.07 0.01 0.93% |
Insider
Quan Vu is COO Officer of 180 Life Sciences
| Age | 52 |
| Phone | 650 507 0669 |
| Web | https://180lifesciences.com |
Quan Vu Latest Insider Activity
Tracking and analyzing the buying and selling activities of Quan Vu against 180 Life stock is an integral part of due diligence when investing in 180 Life. Quan Vu insider activity provides valuable insight into whether 180 Life is net buyers or sellers over its current business cycle. Note, 180 Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell 180 Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Quan Vu six days ago Acquisition by Quan Vu of 25000 shares of Monopar Therapeutics at 30.93 subject to Rule 16b-3 |
180 Life Management Efficiency
The company has return on total asset (ROA) of (0.5162) % which means that it has lost $0.5162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7419) %, meaning that it created substantial loss on money invested by shareholders. 180 Life's management efficiency ratios could be used to measure how well 180 Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Immix Biopharma | 49 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| Peter Facchini | Enveric Biosciences | 61 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Gabriel BA | Immix Biopharma | 38 | |
| JD MBA | Immix Biopharma | N/A | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 36 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Nandan BS | Immix Biopharma | 63 | |
| John Cini | Sonnet Biotherapeutics Holdings | 72 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Donald Picker | Cns Pharmaceuticals | 79 | |
| Robert McRae | Palisade Bio | N/A | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
Management Performance
| Return On Equity | -1.74 | ||||
| Return On Asset | -0.52 |
180 Life Sciences Leadership Team
Elected by the shareholders, the 180 Life's board of directors comprises two types of representatives: 180 Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 180. The board's role is to monitor 180 Life's management team and ensure that shareholders' interests are well served. 180 Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 180 Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sir Feldmann, CoFounder CoChairman | ||
| Eric Lent, Principal CAO | ||
| CPA CPCU, CFO Director | ||
| Quan Vu, COO Officer | ||
| Sir Feldman, CoFounder | ||
| Pr Nanchahal, CoFounder Board | ||
| MBA LLB, Interim Director | ||
| Ozan CFA, CFO Secretary | ||
| Pr MD, CoFounder Board | ||
| Jonathan Rothbard, Chief Officer | ||
| BA MD, CoFounder CoChairman | ||
| Raphael Mechoulam, CoFounder Board | ||
| Jason Assad, Director IR |
180 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 180 Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.74 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 6.46 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Shares Owned By Insiders | 18.13 % | ||||
| Shares Owned By Institutions | 21.32 % | ||||
| Number Of Shares Shorted | 25.91 K | ||||
| Price To Earning | 0.63 X | ||||
| Price To Book | 0.91 X | ||||
| EBITDA | (22.13 M) |
Currently Active Assets on Macroaxis
When determining whether 180 Life Sciences is a strong investment it is important to analyze 180 Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 180 Life's future performance. For an informed investment choice regarding 180 Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in 180 Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 180 Life. If investors know 180 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 180 Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 180 Life Sciences is measured differently than its book value, which is the value of 180 that is recorded on the company's balance sheet. Investors also form their own opinion of 180 Life's value that differs from its market value or its book value, called intrinsic value, which is 180 Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 180 Life's market value can be influenced by many factors that don't directly affect 180 Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 180 Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if 180 Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 180 Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.